»Print   »Share   »Bookmark

2013 Community Outreach Report

Activity and Outcome by Cancer Type


Cancer Screening

 

Skin Cancer

Screening Recommendation:

Timeframe:

Screenings Conducted:

Screening Outcomes:

Follow-up on Positive Findings:

 

 

 

Guidelines followed:

Notes:

 

 

 

Visual inspection suspicious spot(s) on skin

May 15, 2013

46

7 biopsies recommended

- Attendees with a biopsy recommended signed a statement indicating follow-up was required due to a possible cancerous condition.

- Attendees with a biopsy recommended were also contacted with a letter to encourage follow-up with a physician if it didn't happen already.

- Assistance in locating a physician was provided.

American Academy of Dermatology

Sunscreen and sun protection information provided to attendees. List of area dermatologists and resources for those with limited incomes provided to attendees.


Cancer Prevention

 

Lung CT Screening Program

Timeframe:

Screenings Conducted:

Screening Outcomes:

 

 

Follow-up on Positive Findings:

 


Guidelines followed:

 

ProHealthy Community Fair

Timeframe:

Outcomes:

 

 

 

 

 

 

Smoking Cessation Program

Timeframe:

Outcomes:

 

 

Program began in October 2012; ongoing

40 total: 11 in 2013 (as of July 2013)

- 24 positive findings and are in follow up

- 16 negative findings

- 1 lung cancer detected

Positive findings are discussed with patient and follow-up care is identified based on NCCN guidelines. Depending on results, follow-up CT, PET/CT, or surgery is recommended. The Center for Thoracic Care manages appropriate care for these patients.

National Comprehensive Cancer Network (NCCN)

 

 

April 27, 2013

288 people attended. Numerous cancer prevention educational pieces were available along with cancer care coordinators to answer questions. Health screenings, presentations, exercise demonstrations and healthy food samples were available. 

Enrollment site for the American Cancer Society's Cancer Prevention Study 3(CPS-3) in which 64 people completed their in-person appointment during the fair. An additional 74 people were accrued to CPS-3 at two other ProHealth Care sites.

 

 


Ongoing

Comprehensive eight-week program

51 people attended to date (41 people in 2013)



Cancer Quality Measures

Commission on Cancer Standard 4.7 Studies of Quality

Measure: The percentage of class 1 DCIS, clinical stage I and II breast cancer patients at low risk for metastasis diagnosed in CY 2012 who underwent PET, CT and radionuclide bone scans for determining stage. 

Goal: <10%. 

Background on metric: In 2012, the American Society of Clinical Oncology (ASCO) identified five opportunities (“Top Five”) to improve the quality of cancer care and lower costs by reducing the use of clinically unwarranted tests and treatments. ASCO indicates the practices related to the five opportunities are in common use despite the absence of evidence supporting their clinical value. It is understood that the Top Five list is no substitute for the individualized decision making that is the essence of the doctor-patient relationship. Furthermore, the elements of the Top Five list may not be appropriate in certain situations, as could be the case when a patient is enrolled in a clinical trial that demands tests or interventions that are not part of the standard of care.

Number of breast cancer patients the measure impacted: 205

Outcome - Percentage of patients that underwent PET, CT and radionuclide bone scans for determining stage: 2.4%

 

Measure: Percentage of class 1 and 2 clinical stage T1c/T2a prostate cancer patients with a PSA< 10ng/mL and Gleason score =< 6 who were diagnosed in CY 2012 that underwent PET, CT and radionuclide bone scans for determining stage. 

Goal: <10%          

Background on metric: In 2012, the American Society of Clinical Oncology (ASCO) identified five opportunities (“Top Five”) to improve the quality of cancer care and lower costs by reducing the use of clinically unwarranted tests and treatments. ASCO indicates the practices related to the five opportunities are in common use despite the absence of evidence supporting their clinical value. It is understood that the Top Five list is no substitute for the individualized decision making that is the essence of the doctor-patient relationship. Furthermore, the elements of the Top Five list may not be appropriate in certain situations, as could be the case when a patient is enrolled in a clinical trial that demands tests or interventions that are not part of the standard of care.

Number of prostate cancer patients the measure impacted: 11

Outcome - Percentage of patients that underwent PET, CT and radionuclide bone scans for determining stage: 0%

     

Commission on Cancer Standard 4.4 Accountability Measures

Based on 2010 data   

Measure: Radiation therapy is administered within 365 days of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.

Goal: 90%

Number of patients the measure impacted: 46

Outcome: 98%

 

Measure: Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under age 70 with AJCC T1cN0M0, or stage II or III ER & PR negative breast cancer.

Goal: 90%

Number of patients the measure impacted: 6

Outcome: 100%

 

Measure:  Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage II or III ER and/or PR positive breast cancer.

Goal: 90%

Number of patients the measure impacted: 98

Outcome: 96%

 

Measure: Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under age 80 with AJCC stage III (lymph node positive) colon cancer.

Goal: 90%

Number of patients the measure impacted: 11

Outcome: 100%

 

Commission on Cancer Standard 4.5 Quality Improvement Measures

Based on 2010 data      

Measure: At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.

Goal: 80%

Number of patients the measure impacted: 40

Outcome: 100%

 

Measure:  Radiation therapy is considered or administered within 6 months (180 days) of diagnosis for patients under age 80 with clinical or pathologic AJCC staging T4N0M0 or stage III receiving surgical resection for rectal cancer.

Goal: 80%

Number of patients the measure impacted: 6

Outcome: 100%